Sartorius Aktiengesellschaft
Research Sartorius Aktiengesellschaft (SRT3) on Bullrun: valuation model: 36.7% overvalued, market cap EUR 13.74B, P/E 84.5, dividend yield 0.3%. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerSRT3
- ExchangeXETRA
- CountryGermany
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyEUR
- Valuation signal36.7% overvalued
- Market capEUR 13.74B
- P/E84.5
- Dividend yield0.3%
- Financial periodQ1 2026
- RevenueEUR 899.10M
- Net incomeEUR 56.20M
- Free cash flowEUR 111.20M
- Gross margin46.1%
Valuation Snapshot
Bullrun's latest valuation model marks Sartorius Aktiengesellschaft as 36.7% overvalued; latest market cap is EUR 13.74B; P/E is 84.5; dividend yield is 0.3%.
About Sartorius Aktiengesellschaft
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems;
Frequently asked questions
Is Sartorius Aktiengesellschaft overvalued or undervalued?
Bullrun's valuation model currently marks Sartorius Aktiengesellschaft as 36.7% overvalued.
What is Sartorius Aktiengesellschaft's market cap?
Sartorius Aktiengesellschaft's market capitalization is EUR 13.74B.
What is Sartorius Aktiengesellschaft's P/E ratio?
Sartorius Aktiengesellschaft's price-to-earnings (P/E) ratio is 84.5.
Does Sartorius Aktiengesellschaft pay a dividend?
Sartorius Aktiengesellschaft has a dividend yield of 0.3%.
What does Sartorius Aktiengesellschaft do?
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and...